Aprea Therapeutics (NASDAQ:APRE) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Posted by Danessa Lincoln on Nov 6th, 2026

Aprea Therapeutics (NASDAQ:APRE – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02), FiscalAI reports.

Aprea Therapeutics Stock Performance

APRE traded up $0.01 during midday trading on Friday, reaching $0.51. 43,005 shares of the company were exchanged, compared to its average volume of 821,838. The stock has a market capitalization of $6.41 million, a P/E ratio of -0.73 and a beta of 1.74. Aprea Therapeutics has a one year low of $0.41 and a one year high of $1.49. The stock’s 50-day simple moving average is $0.67 and its 200 day simple moving average is $0.75.

Analyst Ratings Changes

Several brokerages have recently issued reports on APRE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Thursday, October 15th. Wedbush dropped their price target on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Aprea Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $2.00 price objective on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Aprea Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $2.80.

Check Out Our Latest Research Report on Aprea Therapeutics

Aprea Therapeutics Company Profile

(Get Free Report)

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its research is centered on small-molecule treatments intended to address molecular abnormalities that contribute to tumor growth and resistance to treatment.

The company’s lead historical program was eprenetapopt, also known as APR-246, an investigational therapy designed to reactivate mutant p53, a tumor-suppressor protein frequently altered in cancer.